Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
186RNL Following WBRT or PCSI for Leptomeningeal Metastases
NCT07674693Phase 1Not yet recruiting
- Sponsor
- NYU Langone Health
- Start
- Jul 2026
- Primary completion
- Jul 2028
01
Overview
Phase 1, open-label, single-arm trial of rhenium (186Re) obisbemeda in leptomeningeal metastases (LM), sponsored by NYU Langone Health. Primary endpoint: Incidence of Dose-Limiting Toxicities. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
rhenium (186Re) obisbemeda
03
Conditions
leptomeningeal metastases (LM)
Beyond the preview
Go deeper on NCT07674693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07674693.